Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

For best results when printing this announcement, please click on link below: Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin Publication marks the first time in nearly two decades that The New England Journal of Medicine has published clinical data on standalone real-time continuous glucose monitoring (CGM) technology, dating back to the creation of the CGM category. Randomized controlled trial demonstrates Dexcom G7 significantly reduces A1C and improves glucose control compared with routine care.

(1) Findings support the role of CGM earlier in Type 2 diabetes care for all people, including those over the age of 65. DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose monitoring (CGM) for adults with Type 2 diabetes not on insulin. This press release features multimedia.

View the full release here: Randomized controlled trial demonstrates Dexcom G7 significantly reduces A1C and improves glucose control compared with routine care. (1) “Publication of CONNECT in The New England Journal of Medicine represents a significant moment for the CGM category. Nearly two decades after NEJM last published clinical data on real-time CGM, we now have compelling evidence demonstrating the impact this technology can have for the millions of people with Type 2 diabetes who are not using insulin,” said Jake Leach, president and CEO of Dexcom. “Dexcom has spent more than 25 years building the CGM category, and today the evidence is undeniable.

" The benefit of CGM use was observed across a broad range of baseline characteristics, including age, sex, race and ethnicity, body mass index, diabetes duration, income, education, health insurance and glucose-lowering medications. (1) “These results provide compelling evidence that CGM use can meaningfully improve glucose outcomes for people with Type 2 diabetes who are not using insulin,” said Roy W. Beck, MD, PhD, Medical Director of the JAEB Center for Health Research and senior author of the study.

“The fact that almost all participants were still using CGM after 26 weeks and most were using it every day indicates that the participants recognized the benefit of CGM and incorporated it into their daily diabetes management. ” The CONNECT study screened 440 participants across 22 primary care sites in the United States. The findings were first presented at the American Diabetes Association’s 2026 Scientific Sessions and add to a growing body of evidence supporting broader access to CGMs for people with Type 2 diabetes. 9% greater reduction than routine care.

0% at 26 weeks. Dexcom G7 users spent approximately five additional hours per day in the 70—180 mg/dL glucose target range compared with routine care. Improvement in this glucose target range was observed within the first week of CGM use. 3% delta between CGM and Control).

9% A1C reduction versus routine care. After 26 weeks, 97% of participants were still using CGM, most on a daily basis. The full study is available on The New England Journal of Medicine website About Dexcom Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years.

Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you’re made of. com Category: IR (1) Oser T, et al.

CGM for Adults with Type 2 Diabetes Not on Insulin: The CONNECT Randomized Controlled Trial. Presented at the 2026 Scientific Sessions of the American Diabetes Association, June 6, 2026. New Orleans, LA; USA. com)